#USA #New York #Microtech #Medinol #Atrial Microsensor

Microtech's Atrial Microsensor Implantation in the U.S.

In an exciting development set to redefine cardiac care, Microtech, a subsidiary of Medinol, has announced the successful implantation of its pioneering atrial pressure microsensor in the United States. This significant milestone occurred on May 16, 2025, at the New York-Presbyterian/Columbia University Irving Medical Center, where two microsensors were expertly implanted by Dr. Koji Takeda, a renowned figure in adult heart transplantation.

The atrial microsensor from Microtech represents an innovative class of medical devices that stand out for their incredibly small size and passive design, devoid of any electronics or antennas. These devices can receive and transmit signals using ultrasound technology, allowing them to be integrated seamlessly into existing implants. This makes them multifunctional devices capable of gathering data and executing several roles simultaneously.

The two sensors implanted pertain to patients who were recipients of Left Ventricular Assist Devices (LVADs) at the medical center. They join the ranks of five previous microsensors that were implanted under similar conditions in Israel, showcasing the potential for international collaboration in advancing cardiac care technology.

Dr. Takeda remarked, "The implantation procedure for the microsensor was straightforward and took about five minutes. We only needed to make minimal adjustments to the existing LVAD insertion technique." This quick and efficient process signifies an essential leap towards enhancing patient care with advanced monitoring capabilities.

Director of the Advanced Heart Failure and Transplantation Program at NewYork-Presbyterian, Dr. Nir Uriel, emphasized the transformative potential of the microsensors, stating, "The ability to monitor both left and right heart pressures non-invasively over time will significantly improve our capacity to optimize patient care. It allows us to transition from a symptom-based to a parameter-based therapy approach." Dr. Uriel, who also holds a professorship at Weill Cornell Medicine, has expressed optimism for the ongoing study, which will involve around 15 patients across both Israel and the U.S.

Medinol's CEO, Dr. Yoram Richter, expressed enthusiasm regarding the early stages of the FIH study, indicating, "We’re thrilled with the progress we've made so far and look forward to demonstrating the practicality, user-friendliness, and accuracy of this system. Additionally, we are working on integrating these microsensors within existing medical devices to realize the full promise of this technology.”

As part of their mission, Medinol aims to initiate a paradigm shift in diagnosis and treatment protocols across a variety of medical fields. The company focuses on creating cutting-edge devices for stent implantation across different body areas, aiming to drastically reduce complications associated with structural heart interventions while providing real-time insights into physiological metrics through implantable sensors.

Through strategic collaborations with healthcare professionals, Medinol is not just addressing current technological challenges but is also looking ahead to develop revolutionary devices that will broaden the scope of healthcare providers both physically and geographically.

For more information regarding Medinol and its innovative approaches, visit www.medinol.com or reach out to Jeff Roach, the Chief Commercial Officer at [email protected].